Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.

Science advances·2026
Same author

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States.

bioRxiv : the preprint server for biology·2026
Same author

Pan-cancer spatial atlas of tertiary lymphoid structures.

Science (New York, N.Y.)·2026
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same author

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Cancer discovery·2026

Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K

Myxofibrosarcoma.

Christina L Roland1, Wei-Lien Wang2, Alexander J Lazar2

  • 1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX 77030, USA.

Surgical Oncology Clinics of North America
|September 4, 2016
PubMed
Summary
This summary is machine-generated.

Myxofibrosarcoma, a soft tissue sarcoma, requires precise MRI for surgical planning. Treatment involves wide resection, but local recurrence and distant metastasis are common challenges.

Keywords:
MRIMyxofibrosarcomaRecurrenceSurgery

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

604

Related Experiment Videos

Last Updated: Mar 15, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
03:53

An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas

Published on: October 10, 2025

604

Area of Science:

  • Oncology
  • Radiology
  • Surgical Oncology

Background:

  • Myxofibrosarcoma is a distinct soft tissue sarcoma characterized by local infiltration.
  • Accurate preoperative imaging is essential for effective management.
  • This sarcoma subtype presents challenges in achieving complete resection and preventing recurrence.

Purpose of the Study:

  • To highlight the critical role of high-quality MRI in preoperative planning for myxofibrosarcoma.
  • To emphasize the standard treatment approach and its complexities.
  • To discuss the common complications and potential adjuvant therapies.

Main Methods:

  • Review of diagnostic imaging modalities, focusing on MRI.
  • Description of surgical resection techniques and reconstruction requirements.
  • Analysis of recurrence patterns and metastatic potential.
  • Evaluation of the role of adjuvant radiation therapy.

Main Results:

  • High-quality MRI is crucial for delineating tumor extent and guiding surgical margins.
  • Wide surgical resection (≥2 cm margin) is the primary treatment.
  • Complex reconstructions may be necessary due to tumor location and infiltrative nature.
  • Local recurrence is frequent; higher-grade tumors have metastatic potential.

Conclusions:

  • Effective management of myxofibrosarcoma hinges on meticulous preoperative MRI and achieving wide surgical margins.
  • Multidisciplinary approaches involving vascular and plastic surgery are often required.
  • Adjuvant radiation therapy may play a role in mitigating local recurrence rates.